TiGenix n.v.
Quick facts
Phase 3 pipeline
- ChondroCelect implantation · Orthopedics / Rheumatology
ChondroCelect is an autologous cultured chondrocyte implant that replaces damaged cartilage by transplanting the patient's own expanded cartilage cells into the defect site.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about TiGenix n.v.
What is TiGenix n.v.'s pipeline?
TiGenix n.v. has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include ChondroCelect implantation.
Related
- Sector hub: All tracked pharma companies